TRIM66 Inhibitors

MG132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. TRIM66, as part of the TRIM family, has an E3 ubiquitin ligase activity. MG132's inhibition of the proteasome can lead to the accumulation of ubiquitinated proteins, indirectly inhibiting the functional activity of TRIM66 by overwhelming its ligase activity.

Bortezomib is another proteasome inhibitor that can cause an accumulation of ubiquitinated proteins. This can indirectly inhibit TRIM66 by potentially sequestering its E3 ligase activity on an overwhelming number of substrates, rendering it less effective.

MLN4924 is a NEDD8-activating enzyme inhibitor which can prevent the neddylation of cullin proteins, a process important for the function of cullin-RING E3 ubiquitin ligases. TRIM66's function could be indirectly inhibited as the disruption of neddylation may affect overall ubiquitination processes, including those mediated by TRIM66.

Chloroquine is an autophagy inhibitor that raises the pH in lysosomes, inhibiting their function. By inhibiting autophagy, chloroquine could lead to reduced degradation of ubiquitinated proteins, potentially resulting in feedback inhibition of TRIM66's E3 ligase activity due to substrate accumulation.

Ixazomib is a proteasome inhibitor used for multiple myeloma. Similar to other proteasome inhibitors, its action can lead to the accumulation of TRIM66 substrates, thus indirectly inhibiting TRIM66's ability to tag additional proteins for degradation.

PYR-41 is a specific inhibitor of the ubiquitin-activating enzyme E1. By inhibiting the initial step of ubiquitination, PYR-41 can indirectly inhibit the function of TRIM66 by reducing the availability of ubiquitin for its ligase activity.

Lactacystin is a specific inhibitor of the proteasome that irreversibly binds to its catalytic subunit. This inhibitor can indirectly inhibit TRIM66 by causing a buildup of ubiquitinated proteins and hindering TRIM66's ability to ubiquitinate new substrates.

Nutlin-3 is an MDM2 antagonist that prevents the ubiquitination and subsequent degradation of p53. The stabilization of p53 can have various downstream effects, potentially including the modulation of proteins that interact with TRIM66, indirectly inhibiting its function.

Epoxomicin is a selective proteasome inhibitor that binds irreversibly to the proteasome's active sites. Similar to other proteasome inhibitors, it can lead to an indirect inhibition of TRIM66 by preventing the degradation of its ubiquitinated substrates.